(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Germany sees third consecutive diesel price record after rule change - 2Sustaining Public activity and Connections: Key Methodologies
- 3Rescuers attempt to dig free whale stranded on Germany's Baltic coast
- 4SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
- 5Find the Standards of Powerful Cooperation: Accomplishing Cooperative energy and Coordinated effort
- A Couple of Reasonable Guitars for 2024
- Well known Tea Brands for Each Tea Sweetheart
- Netflix Faces Wider Fallout After Italy Court Orders Refunds, Price Cuts
- Sahel coups push Africa to top of global democratic declines, report finds
- Figure out How to Analyze Medical attendant Compensation Patterns Across Different Specializations
- FDA approves Wegovy pill for weight loss
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- Vote In favor of Your Favored Language Interpretation Administration
- The secret appeal of Harlan Coben’s messy, addictive TV thrillers
